Relmada Therapeutics, INC Schedule 13G passive stakes

Squadron Master Fund LP, along with its investment advisor and partners, has reported beneficial ownership of 7.0% of Relmada Therapeutics, Inc. common stock.

Venrock Healthcare Capital Partners and affiliates have reported a 6.2% beneficial ownership stake in Relmada Therapeutics, Inc.

Adage Capital Management, L.P. and its affiliates have reported beneficial ownership of 4,763,158 shares, representing 4.54% of the outstanding common stock of Relmada Therapeutics, Inc.

Commodore Capital LP, along with affiliated entities and individuals, has reported beneficial ownership of 5,505,527 shares, representing 5.1% of Relmada Therapeutics, Inc.'s common stock.

Squadron Master Fund LP and related entities have disclosed a 9.99% beneficial ownership stake in RELMADA THERAPEUTICS, INC., totaling 7,395,510 shares.

Spruce Street Capital LP and its co-managing members have reported a 5.57% beneficial ownership stake in Relmada Therapeutics, Inc. common stock.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.82% beneficial ownership in Relmada Therapeutics, Inc. common stock.

Janus Henderson Group plc has reported a 10.1% beneficial ownership stake in Relmada Therapeutics, Inc., holding 7,439,415 shares of common stock.

Ikarian Capital and Neil Shahrestani have reported a 4.8% passive beneficial ownership stake in Relmada Therapeutics, Inc. as of September 30, 2025.

Squadron Master Fund LP and affiliates report increased passive beneficial ownership in Relmada Therapeutics, Inc., reaching up to 9.9% of common stock.

Squadron Master Fund LP and its affiliates have disclosed a passive ownership stake exceeding 5% in RELMADA THERAPEUTICS, INC., as detailed in a recent Schedule 13G filing.